Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-rituximab
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**225Ac-rituximab** is an experimental actinium-225 radiolabeled anti-CD20 radioimmunoconjugate based on rituximab. Rituximab directs the construct to CD20-expressing B cells, while the decay of actinium-225 and its daughter radionuclides delivers high-linear-energy-transfer alpha-particle radiation that causes localized cytotoxic DNA damage. The exact term has been reported in preclinical research as a nonspecific control antibody in studies of targeted alpha-particle therapy, including comparison against 225Ac-substance P in NK1 receptor-expressing glioma cells. No clinical development program, marketed product, or assigned nonproprietary name specific to the 225Ac conjugate was identified in the provided sources.
- Other names
- 225Ac-Rituximabactinium-225-labeled rituximabactinium225-labeled rituximabactinium 225-labeled rituximab
02
Targets
Beyond the preview
Go deeper on 225Ac-rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-rituximab.